Moderna, Inc. — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Moderna reported Q2 2026 revenue of $145 million (flat vs. $142M in Q2 2025) and net loss of $800 million ($1.97 per share). The company narrowed 2026 GAAP operating expense guidance by ~$200 million and improved year-end cash outlook to $4.7–5.2 billion (from prior estimate). Key updates: mFLUSIVA received unanimous VRBPAC recommendation with August 5 PDUFA date for potential fifth product approval; mRNA-1403 (norovirus) failed Phase 3 interim efficacy criteria but trial continues with additional cohort enrollment; intismeran Phase 3 melanoma data expected in 2026. A $950 million litigation settlement paid in July 2026 was pre-disclosed.
Why this rating
Routine quarterly earnings with modest operational improvements. Revenue stalled; losses persist but 5% narrower YoY. Pipeline progress (mFLUSIVA near approval, melanoma data expected) is meaningful but contingent. Cash runway adequate (~47–53% of market cap) but declining. Norovirus setback and operating expense cuts show normal execution, not trajectory change relative to ~$10B market cap.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.